Jacksonville, FL - Data from a pharmacodynamic study suggests that acute coronary syndrome (ACS) patients can be safely switched from maintenance clopidogrel (Plavix, Bristol-Myers ...
There is no benefit in terms of 1-year clinical outcomes for STEMI patients who receive crushed over integral prasugrel tablet loading doses in the ambulance, according to new data from the COMPARE ...
Please provide your email address to receive an email when new articles are posted on . In the ISAR-REACT 5 randomized trial, Maurizio Menichelli, MD, head of cardiology at Fabrizio Spaziani Hospital ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among patients who underwent PCI for ACS and then had ...
Crushing prasugrel tablets before administering them to STEMI patients in the ambulance leads to more prompt and potent platelet inhibition compared with leaving them whole, according to an analysis ...
A reduced dose of prasugrel compared with the standard dose of ticagrelor was associated with maintained anti-ischemic efficacy and safety in elderly or low-weight patients with acute coronary ...
In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...
DALLAS, TX — Long-term ischemic and bleeding risks climb with advancing age in elderly patients medically managed for acute coronary syndromes (ACS), as might be expected, but adding low-dose ...
While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an ...
Reduced dose of prasugrel associated with reduced risk for bleeding in low-weight or elderly patient
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...
NEW YORK, Oct 23 (Reuters) - A small study presented on Monday suggests Eli Lilly and Co.'s experimental blood clot preventer prasugrel works faster and could be more effective than the commonly used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback